Join to View Full Profile
4921 Parkview Pl# DvSaint Louis, MO 63110
Phone+1 800-647-2098
Fax+1 314-362-3192
Dr. Mehta-Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2010 - 2012
Northwestern University The Feinberg School of MedicineClass of 2009
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2016 - 2026
NY State Medical License 2011 - 2018
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Minimal Residual Disease in Peripheral T-cell Lymphoma Start of enrollment: 2017 Jul 31
- Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Start of enrollment: 2021 Oct 08
Roles: Principal Investigator, Contact, Study Chair
- Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma Start of enrollment: 2021 Apr 29
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsAlopecia areata after mogamulizumab treatmentNeel S. Raval, Nora A. Alexander, Karlee De Monnin, Christine C. Yokoyama, Neha Mehta-Shah
JAAD Case Reports. 2021-11-01 - An Update on the Current Genomic Landscape of Breast Implant-Associated Anaplastic Large Cell Lymphoma.Sean Harrop, Neha Mehta-Shah, Criselle D'Souza, Ella R. Thompson, Anand K. Deva
Cancers. 2021-09-30 - 19 citationsRomidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohortsNeha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan
American Journal of Hematology. 2021-07-12
Abstracts/Posters
- Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...Neha Mehta-Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Aggressive Non-Hodgkin Lymphomas: It's Getting Personal61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Black Patients with CLL Face Shorter Overall SurvivalJune 5th, 2022- What Is the Optimal Frontline Treatment for PTCL?June 23rd, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
